A Dynamic Model for Therapy Selection in ICU Patients with VAP

Theodore Charitos\textsuperscript{1}, Stefan Visscher\textsuperscript{2}, Linda C. van der Gaag\textsuperscript{1}, Peter Lucas\textsuperscript{3}, and Karin Schurink\textsuperscript{2}

\textsuperscript{1} Dept. of Inform. and Comp. Sciences, Utrecht University, The Netherlands
\textsuperscript{2} Dept. of Internal Medic. and Infect. Diseases, University Medical Center Utrecht, The Netherlands
\textsuperscript{3} Inst. for Comp. and Inform. Sciences, Radboud University, Nijmegen, The Netherlands

Abstract

Treating ventilator-associated pneumonia in mechanically ventilated patients in intensive care units is seen as a clinical challenge. In this paper, we develop a dynamic-decision model that explicitly captures the development of the disease over time. To represent the dependencies between the variables involved in a compact way we use a dynamic Bayesian network and combine it with the framework of partially observable Markov decision processes to choose optimal antimicrobial therapy for respiratory tract infections. We discuss implementation issues and modelling advantages of our model and demonstrate its use for a number of real patients.

1 Introduction

Many patients admitted to an intensive care unit (ICU) need respiratory support by a mechanical ventilator, which promotes the development of ventilator-associated pneumonia (VAP) in these patients. Effective and fast treatment of VAP is seen as an issue of major significance. The difficulty in diagnosing VAP is in the lack of an accurate, non-invasive (that is, patient-friendly) gold standard; VAP is therefore diagnosed by taking a number of different clinical features into account\textsuperscript{[9; 14]}.

A prominent role in the development of VAP is played by two stochastic processes: colonisation of the laryngotraechobronchial tree by pathogens and the onset and development of pneumonia. A dynamic Bayesian network, called dVAP was developed that explicitly captures the temporal relationships between the variables involved\textsuperscript{[5]}. This network takes into account the patient’s characteristics from earlier days when performing diagnosis. The numerical part of the network was constructed from estimations by infectious-disease experts and from the literature. In a later stage these probabilities were updated through machine learning using collected patient data, which resulted in a better diagnostic performance of the model.

The treatment of VAP is seen as a significant problem by ICU doctors. Firstly, many of the patients suffering from VAP are severely ill. Secondly, the presence of multi-resistant bacteria in clinical wards, in particular the ICU, makes prescription of antibiotics with a spectrum as narrow as possible essential; the description of broad-spectrum antibiotics promotes the development of antimicrobial resistance, and should therefore be avoided when possible. In this paper, we address optimal therapy selection using the dVAP model. For this purpose, we focus on the framework of partially observable Markov decision processes (POMDPs)\textsuperscript{[1; 7; 12; 15]} for sequential decision making.

Although the standard POMDP framework in essence allows us to capture the main elements of choosing a therapy of VAP, it cannot be used directly, mainly because: (1) the number of parameters required can be huge, and (2) exact methods for solving the problem are computationally very demanding and only small problems can be solved exactly. In view of these considerations, we extend the dVAP network and construct a dynamic-decision model that incorporates the uncertainty included in the treatment procedure. We then use the Perseus algorithm for its evaluation\textsuperscript{[16]}. Perseus is a point-based approximate value-iteration algorithm for POMDPs that achieves competitive performance both in terms of solution and speed comparing to alternative (and more complex) algorithms in the literature\textsuperscript{[3]}. Perseus can moreover be easily implemented in practice\textsuperscript{[13]}. Perseus, however, is designed for problems without any structure among the variables representing the state of the process. We enhance the applicability of Perseus for our structured domain to take advantage of the factorisations and independencies among the variables included in the dVAP model.

We tested the resulting model on a group of patients drawn from the files of the ICU of the University Medical Center Utrecht in the Netherlands. The solutions obtained indicate that our dynamic-decision model provides a useful framework for solving and analysing complex decision problems. Our results in fact advocate further application of Perseus in structured domains of other medical therapy problems.

The remainder of this paper is organised as follows. In Section 2, we describe the dVAP network for the diagnosis of VAP. In Section 3 we describe the basics of the POMDP framework and of the Perseus algorithm; in Section 4 we discuss modelling and computational issues related to applying Perseus to decision making for patients with VAP. Section 5 presents and discusses the results from an evaluation study. Finally, the paper ends with our conclusions in Section 6.
2 Diagnosing VAP

We begin by discussing the pathophysiology of VAP and then describe the dVAP model that captures the development of VAP.

2.1 Pathophysiology of VAP

Ventilator-associated pneumonia is, when looking at a daily level, a low-prevalence disease occurring in mechanically-ventilated patients in critical care and involves infection of the lower respiratory tract [2]. In contrast to infections of more frequently involved organs (such as the urinary tract), for which mortality is low, ranging from 1 to 4%, the mortality rate for VAP ranges from 24 to 50% and can reach 76% for some high-risk pathogens. Variables that change due to the development of VAP, among others, are an increased body temperature, an abnormal amount of coloured sputum, signs on the chest X-ray, the duration of mechanical ventilation, and an abnormal number of leucocytes.

The relationship between the colonisation by pathogens and the development of pneumonia is captured as follows. Periodically, a sample of the patient’s sputum is cultured at the laboratory. When the culture shows a number of colonies of a particular bacterium that is above a particular threshold, the patient is said to be colonised by this bacterium. The seven groups of microorganisms that occur most frequently in critically ill patients and cause colonisation, are modelled in the diagnostic part of the network. Information about which bacterium or bacteria are currently present in a patient and the current signs and symptoms constitute the basis for choosing optimal antimicrobial treatment.

2.2 A dynamic model for diagnosis

A dynamic Bayesian network (DBN) is a graphical model that encodes a joint probability distribution on a set of stochastic variables, explicitly capturing the temporal relationships between them. More formally, let $V_n = (V_1^n, \ldots, V_m^n)$, $m \geq 1$, denote the set of variables at time $n$. Then, a dynamic Bayesian network is a tuple $(B_1, B_2)$, where $B_1$ is a Bayesian network that represents the prior distribution for the variables in the first time slice $V_1$, and $B_2$ defines the transitional relationships between the variables for two consecutive time slices, so that for every $n \geq 2$

$$p(V_n | V_{n-1}) = \prod_{i=1}^{m} p(V_i^n | \pi(V_i^n))$$

where $\pi(V_i^n)$ denotes the set of parents of $V_i^n$, for $i = 1, \ldots, m$.

DBNs are usually assumed to be time invariant, which means that the topology and the parameters of the network per time slice and across time slices do not change. Moreover, the Markov property for transitional dependence is assumed, which means that $\pi(V_i^n)$ can include variables either from the same time slice $n$ or from the previous slice $n - 1$, but not from earlier time slices [10]. Then, by unrolling $B_2$ for $N$ time slices, a joint probability distribution $p(V_1, \ldots, V_N)$ is defined for which the following decomposition property holds:

$$p(V_1, \ldots, V_N) = \prod_{n=1}^{N} \prod_{i=1}^{m} p(V_i^n | \pi(V_i^n))$$

Monitoring in a DBN is the task of computing the probability distribution for a set of variables of interest $X_n \subset V_n$ at time $n$ given the observations that are available up to and including time $n$.

2.3 Modelling and computational issues

An overview of the structure of the dynamic network constructed for the diagnosis of VAP [5] is depicted in Figure 1. The dVAP network includes two interacting dynamic hidden processes, modelled by the compound variables colonisation (7 variables) and pneumonia (8 variables). The process of colonisation is influenced by three input variables: hospitalisation, mechanical ventilation and previous antibiotics, and one hidden variable aspiration that in essence controls its dynamics. We note that the variables hospitalisation and mechanical ventilation are observed for a period that is longer than the transition interval of the model. The variables thus are modelled as affecting adjacent time slices. The variable previous antibiotics represents the effect of previous medication to the patient on the process of colonisation. The symptoms and signs of pneumonia are depicted in Figure 2. These variables are included in the diagnostic part of the network.

The practicability of the dVAP network depends to a large extent on the computational burden of inference with the network. For diagnosing patients with VAP, monitoring is performed at each time. For this purpose, the interface algorithm can be applied [10]. This algorithm is an extension of the junction-tree algorithm for inference with Bayesian networks in general [6] and efficiently exploits the forward interface of a dynamic network. Recall that the forward interface is the set of variables at time slice $n$ that affect some variables at time slice $n + 1$ directly. Note that the interface algorithm is linear in the total number of time slices and for large time scopes, the computation time can prove to be prohibitive in practice.

Recent results show that, in case consecutive similar observations are obtained, the probability distribution of the hidden process converges to a limit distribution within a given level of accuracy [41]. After some number of time slices, therefore, there is no need for further inference as long as similar observations are obtained. The phenomenon of consecutive similar observations was evident for several patients in the ICU files. For example, for these patients
After taking action $s$, the expected reward for taking action $\alpha$ is $r(b, \alpha) = \mathbb{E}(\tau | b, \alpha)$. The optimal policy $\mu^*: b \rightarrow A$ is defined as

$$
\mu^*(b) = \arg\max_{\alpha \in A} \left[ r(b, \alpha) + \gamma \sum_{o \in \Theta} p(o | b, \alpha) V^*(\tau(b, \alpha, o)) \right]
$$

In order to compute the value function $V^*(b)$ in equation (1) we use the value iteration algorithm [15], which guarantees that the sequence of value function approximations $V_i$ defined as

$$
V_i(b) = \max_{\alpha \in A} \left[ r(b, \alpha) + \gamma \sum_{o \in \Theta} p(o | b, \alpha) V_{i-1}(\tau(b, \alpha, o)) \right]
$$

converges to the optimal solution. An important property of this approximation sequence is that the value functions $V_i(b)$ in equation (2) are piecewise linear and convex, which allows for computing the update in finite time for the complete belief space [11]. However, the computational cost of doing so is high for all but trivial problems, and thus several methods have been proposed in the literature that try to approximate the optimal value function $V^*$ [8].

### 3.2 The Perseus algorithm

Perseus is an efficient point based approximate value iteration algorithm for POMDPs [16]. The main idea is to use a set of reachable belief states $B$ that are sampled from the belief simplex to perform value function updates, ensuring that in each iteration the new value function is an upper bound to the previous value function, as estimated on the sampled set of belief states. The intuition behind this approach is that in most practical problems the belief simplex is sparse, in the sense that only a limited number of belief states can ever be reached by letting the hidden process interact with its environment. The algorithm performs value function updates, making sure that in each step the new value function estimate $V_{i+1}(b)$ is an upper bound for $V_i(b)$ for all $b \in B$. The major advantage of Perseus is that in each iteration $i$ it uses only a (random) subset of states in $B$ until the value $V_i(b)$ of every $b \in B$ has improved or remained the same. This property makes the algorithm efficient even in problem domains with large state spaces compared to other approximate methods [8]. We note, however, that the Perseus algorithm has been designed for POMDPs...
used to model the conjunctive effect of antibiotics on the model includes the hidden compound variable selected therapy on the probability distribution of $V_{AP}$. Fig-
we add a decision-theoretic part that represents the effect of broadness of spectrum.

is a trade-off between maximising coverage and narrowing pathogens to particular antibiotics. A causal in-
\[ 9 \] . The prescribed treatment thus
broadness of its spectrum gives the final utility of pre-
strum antibiotics. The problem of prescribing unnecessarily more difficult to eradicate. Here, we need broader spec-
antibiotics. The problem of prescribing unneces-
sistance, which means that pathogens are no longer sus-
tify in health-care [2]. Our dynamic-
decision model now incorporates the idea of prescribing antibiotic spectra as narrow as possible. The narrower the spectrum, the higher the preference. How well the pathogen is covered by an antibiotic times the preference of the broadness of its spectrum gives the final utility of pres-
thesis this antibiotic [9]. The prescribed treatment thus is a trade-off between maximising coverage and narrowing breadth of spectrum.

To incorporate for decision making in the dVAP model, we add a decision-theoretic part that represents the effect of selected therapy on the probability distribution of VAP. Figure 3 depicts the resulting model. The dynamic-decision model includes the hidden compound variable $\text{susceptibility}$ (8 variables) that represents the susceptibility of the suspected pathogens to particular antibiotics. A causal independence model, known as the noisy-AND gate [9], is used to model the conjunctive effect of antibiotics on the susceptibility of pathogens. The model thus includes 24 bi-

tary hidden variables with $2^{24}$ possible configurations. The $\text{therapy}$ variable includes 26 different antibiotics or combi-

with flat belief state, that is, for states without any type of internal structure. To incorporate Perseus into our approach to solving the dynamic-decision model for VAP, we have to enhance its applicability to more structured domains. We discuss such modifications in the next section.

4 Decision making for VAP

The aim of our dynamic-decision model is to aid clinicians in dealing with patients with suspected VAP. Optimal antimicrobial therapy for VAP is selected by balancing the expected efficacy of treatment, which is related to the number of pathogens causing the infection, against the spectrum of antimicrobial treatment. Each of the seven mod-
elled groups of pathogens are susceptible to particular antibiotics. Some of these pathogens are easy to cover. For these pathogens, a narrow or even very narrow antimicro-
broad spectrum is sufficient. Some pathogens, however, are more difficult to eradicate. Here, we need broader spectrum antibiotics. The problem of prescribing unnecessarily broad-spectrum antibiotics is the occurrence of antibiotic resistance, which means that pathogens are no longer sus-
ceptible to a particular antibiotic. Antibiotic resistance is a well-known problem in health-care [2]. Our dynamic-
decision model now incorporates the idea of prescribing antibiotic spectra as narrow as possible. The narrower the spectrum, the higher the preference. How well the pathogen is covered by an antibiotic times the preference of the broadness of its spectrum gives the final utility of pres-
sing this antibiotic [9]. The prescribed treatment thus is a trade-off between maximising coverage and narrowing breadth of spectrum.

As a result of the above modifications, the set $\Theta$ includes to 768 possible combinations, and thus is smaller in size than the original set by a factor 1800. The afore-
mentioned considerations were used initially to create a set of reachable belief states $B$ and then to apply Perseus with $\gamma = 0.95$. In our experiments on a 2.4 GHz Intel(R) Pen-
tium computer, creating $B$ took 1.5 seconds per belief state, while computing an optimal policy took approximately one minute using a total of 10000 sampled belief states.

5 Evaluation

We examined the performance of our dynamic-decision model on 5 patients diagnosed with VAP randomly selected from a prospectively collected database of ICU patients. Using the dVAP network we monitored these patients and computed their belief state per day for a total of 10 days.
patients the recommended antibiotics did not cover the observed pathogens. A possible explanation of this suboptimal performance of the model is that its decisions are strongly affected by the probability of VAP at each time and less by the colonising pathogens; that is, the prescription of antibiotics is heavily dominated by \( p(\text{VAP}) \), while less weight is given to the presence of colonisation data.

Contrary to an earlier evaluation of the diagnostic performance of the dVAP network [5], we took into account the sparse colonisation data that existed in the datasets of some patients. In contrast to the data for the observable variables that were readily available, the colonisation data were provided by the laboratory from sputum cultures and took on average 48 hours to become available. Also, these data concerned only a (small) subset of colonisation pathogens and were observed for a few days (maximum 3). To process the colonisation data, we assumed that whenever there was a positive culture for a specific pathogen on a specific day, the values of the other non-observed pathogens were set to negative. We are aware that this assumption should be used with care. More specifically, the transition matrices estimated by the expert [5] suggested that, under particular conditions, if a pathogen is positive (negative) on one day then it cannot be negative (positive) on the next day. For one patient for example, we noticed upon processing the available data, that on day 8 we assumed the presence of \( S.\)aureus and \( S.\)pneumoniae to be negative while these two pathogens were actually observed to be positive on day 9. To resolve this issue, we made no assumption about these two pathogens on day 8 and left their value as unobserved.

We compared the recommended decisions from the model with an expert opinion as to the most appropriate antibiotics to cover the likely pathogens. The results were not entirely satisfactory in the opinion of the expert. For one patient, for whom no colonisation data were available, we found that the decisions recommended by the model were acceptable; for two patients the model recommended too broad a spectrum antibiotics, while for the other two patients the recommended antibiotics did not cover the observed pathogens.

### Table 1: The best two recommendations (and their spectrum in parenthesis) at each time slice for two patients.

<table>
<thead>
<tr>
<th>day</th>
<th>( p(\text{VAP}) )</th>
<th>+ colon.path.</th>
<th>antibiotic</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>0.2295</td>
<td>-</td>
<td>none meropenem (b)</td>
</tr>
<tr>
<td>3</td>
<td>0.0049</td>
<td>Enterobacteria2</td>
<td>cotrimoxazol (n)</td>
</tr>
<tr>
<td>4</td>
<td>0.0052</td>
<td>-</td>
<td>cotrimoxazol (n)</td>
</tr>
<tr>
<td>5</td>
<td>0.0848</td>
<td>-</td>
<td>cotrimoxazol (n)</td>
</tr>
<tr>
<td>6</td>
<td>0.3401</td>
<td>-</td>
<td>cotrimoxazol (n)</td>
</tr>
<tr>
<td>7</td>
<td>0.0363</td>
<td>-</td>
<td>none erythromycin (vn)</td>
</tr>
<tr>
<td>8</td>
<td>0.0017</td>
<td>P. aeruginosa Enterobacteria2</td>
<td>cotrimoxazol (n)</td>
</tr>
<tr>
<td>9</td>
<td>0.0012</td>
<td>P. aeruginosa Enterobacteria2</td>
<td>cotrimoxazol (n)</td>
</tr>
<tr>
<td>10</td>
<td>0.0046</td>
<td>-</td>
<td>cotrimoxazol (n)</td>
</tr>
</tbody>
</table>

(a) patient A

<table>
<thead>
<tr>
<th>day</th>
<th>( p(\text{VAP}) )</th>
<th>+ colon.path.</th>
<th>antibiotic</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>0.028</td>
<td>-</td>
<td>cotrimoxazol (n)</td>
</tr>
<tr>
<td>3</td>
<td>0.0344</td>
<td>-</td>
<td>cotrimoxazol (n)</td>
</tr>
<tr>
<td>4</td>
<td>0.1905</td>
<td>Enterobacteria2</td>
<td>cotrimoxazol (n)</td>
</tr>
<tr>
<td>5</td>
<td>0.5929</td>
<td>-</td>
<td>cotrimoxazol (n)</td>
</tr>
<tr>
<td>6</td>
<td>0.5445</td>
<td>-</td>
<td>cotrimoxazol (n)</td>
</tr>
<tr>
<td>7</td>
<td>0.9823</td>
<td>-</td>
<td>cotrimoxazol (n)</td>
</tr>
<tr>
<td>8</td>
<td>0.9791</td>
<td>Acinetobacter</td>
<td>ceftazidim (i)</td>
</tr>
<tr>
<td>9</td>
<td>0.9450</td>
<td>Acinetobacter</td>
<td>cotrimoxazol (n)</td>
</tr>
<tr>
<td>10</td>
<td>0.9918</td>
<td>-</td>
<td>cotrimoxazol (n)</td>
</tr>
</tbody>
</table>

(b) patient B

In view of the above considerations, we enhanced our decision model to incorporate the influence of the colonisation data on the recommended decision in a more appropriate fashion. For each colonisation (group of) pathogen(s) found to be positive on a given day, we force the model to prescribe antibiotics to cover this pathogen. In this way our model considers a conglomeration of different decision plans that are influenced by the presence of positive pathogens in the patient’s dataset. To cope with the sparsity of the colonisation data, we use the enhanced model for the following two days as well. As a result, the clinician is presented with a therapy plan that aims to cover positive observed pathogens for at least three days. For the remaining days for which no colonisation data were available, the original decision model was used. The evalua-
tion now showed now that the new recommendations better comply with the expert’s recommendations.

We discuss the results for two patients in order to convey how our dynamic-decision model might be employed clinically, and to point out some of its limitations. For patient A, the dVAP network assigns a small probability to VAP for almost all the days. As a consequence, the decision not to prescribe any antibiotic is always recommended by the model. However, positive cultures of pathogens are observed for the days 3, 8 and 9. For these days (and for the next two days) the antibiotic cotrimoxazol (narrow spectrum) is recommended first. This recommendation reflects the ability of the model to prescribe an antibiotic even if the probability of VAP is very small. We note, however, that on day 2, the model suggests the antibiotic meropenem. This recommendation is far too broad for this patient, and raises the question whether alternative utility models might alleviate this problem. For patient B, the dVAP network assigns quite early (day 5) a relatively high probability to VAP which even further increases in the following days. In addition, positive cultures of pathogens are observed for the days 4, 8 and 9. Our dynamic-decision model takes into account both the high probability of VAP and the positive cultures to recommend appropriate antibiotics that belong to a narrow spectrum whenever possible. This is evident in the recommendations for days 4 to 7, while for days 8 to 10 the recommendation belongs to the intermediate or broad spectrum. The predictions made and the therapy suggested by the model for both patients are shown in Table 1.

6 Conclusions

We have described the development of a dynamic-decision model that is able to assist clinicians in the clinical management of ventilator-associated pneumonia. For the purpose of computing appropriate decisions from the model, we applied the framework of partially observable Markov decision processes for modelling the action-outcome uncertainty and partial observability. The application and potential of the POMDP framework to medical planning has been discussed in [12] and successfully explored in [7]; in the latter work, a hierarchical Bayesian network was used to represent the disease dynamics and to decrease the computational burden involved. Since exact computation in a POMDP is intractable, we discussed the application of the Perseus algorithm to our problem, in which the belief state of the hidden process is structured. The solutions obtained for a small set of patients from an initial evaluation of our model showed that POMDPs could provide a useful framework for solving complex decision problems. We feel that the promising results justify further refinement and extension of our current model as well as application of our framework to other complex structured decision problems [11].

Acknowledgements

This research was (partly) supported by the Netherlands Organization for Scientific Research (NWO). The first author would like to thank Matthijs Spaan and Nikos Vlassis for their help in implementing Perseus.

References